Chengda Biotech: Influenza virus split vaccine enters Phase I clinical trial.

Nasdaq Biological announced that the flu virus split vaccine developed by its wholly-owned subsidiary, Benxi Subsidiary, has been approved by the National Medical Products Administration for clinical trials, and preparations have been completed to officially enter the Phase I clinical trial stage. The flu vaccine can prevent flu, and the antigen content of the company's vaccine is higher, with a stronger immune effect, and is expected to fill a gap in the domestic market. However, the vaccine development cycle is long, with many stages, and the progress and results, as well as the market launch schedule, are uncertain, so the short-term impact on the company's operations is limited.